2022年10月6日

2022年10月6日美國東部夏令時上午07:00馬薩諸塞州坎布裏奇-(美國商業資訊)- Rectify Pharmaceuticals, Inc.(“Rectify”)是一家生物技術公司，開發恢複和增強ABC轉運蛋白功能的小分子疾病修飾療法，繼續壯大其高級領導團隊。Robert Hughes博士最近加入公司擔任藥物發現和臨床前開發執行副總裁，Xiaobing Li博士加入公司擔任首席開發官。總裁兼首席執行官Rajesh Devraj博士說:“我們非常高興地歡迎Rob和Xiaobing加入我們的團隊，擴大了我們管理團隊的深度。”“Rob在藥物發現和臨床前開發的運營和戰略監督方麵具有深厚的專業知識，曾在製藥和小型生物技術公司為多個疾病領域的十幾種開發分子的交付做出貢獻。Xiaobing在項目組合管理和跨職能項目團隊領導方麵具有豐富的經驗，從發現階段到NDA提交。作為首席開發官，她將在推動正向功能調節劑(PFMs)從發現到臨床開發的過程中發揮關鍵作用。他們的專業知識將是我們繼續推進管道以恢複和增強ABC傳輸器功能的關鍵。”此前，Hughes博士曾擔任Atlas Venture的駐場企業家，以及繳械治療公司的分子發現副總裁。在繳械公司，Hughes博士是團隊的關鍵成員，在2020年被禮來公司收購之前交付了兩個開發候選人。 Prior to this, Dr. Hughes held positions at Boehringer-Ingelheim and Pfizer working across multiple therapeutic areas, including cardiometabolism, neurodegeneration, and immunology, and various target classes advancing programs from conception to the clinic. Over the course of his career, Dr. Hughes contributed to the delivery of 12 development candidate molecules across multiple target classes. Dr. Li brings deep experience driving multiple programs from discovery through investigational new drug (IND) application, and onwards to clinical regulatory submissions and market registration. Most recently, she served as Chief Portfolio Officer at Clover Pharmaceuticals, leading research and development (R&D) strategy. Previously, she was Vice President, Head of Program Leadership and Portfolio Management at Voyager Therapeutics. Prior to this, Dr. Li was a Senior Director, Global Program Leader for Zulresso® at Sage Therapeutics. Trained as a medicinal chemist, Dr. Li spent fourteen years at Janssen Pharmaceutical Companies followed by working at Alkermes and Ironwood Pharmaceuticals in various leadership positions with a focus on R&D program execution and delivery of products. About Rectify Pharmaceuticals, Inc. (“Rectify”) Rectify is developing Positive Functional Modulators (PFMs) – disease-modifying therapies that restore and enhance ABC transporter function to address the underlying cause of serious ABC transporter mediated diseases. Rectify is the first company to directly address the untapped therapeutic potential of the ABC transporter target class. ATP-binding cassette (ABC) transporters are a 48-member superfamily of membrane-bound proteins that actively export a diverse range of substrates (e.g., lipids, ions, peptides, and salts) across lipid membranes. Rectify has built a breakthrough ABC transporter product platform that is enabling efficient and rapid discovery of first-in-class small molecule therapies that restore and enhance ABC transporter function for rare and common liver, biliary, eye and CNS diseases. Rectify was founded, seeded, and launched by Atlas Venture, who led the $100M Series A round with a world-class syndicate including Omega Funds, Forbion Capital Partners, and Longwood Fund. The company is headquartered in Cambridge, Massachusetts. For more information, please visit www.rectifypharma.com . Contacts